Osteoporos Int 11:83–91PubMedCrossRef 31. Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841–1850PubMedCrossRef 32. Stepan JJ, Alenfeld F, Boivin G et al (2003) Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul
37:225–238PubMed 33. Hansdottir H, Franzson L, Prestwood K, Sigurdsson G (2004) The effect of raloxifene on markers of bone turnover in older women living in Bafilomycin A1 long-term care facilities. J Am Geriatr Soc 52:779–783PubMedCrossRef 34. Marie PJ (2005) Strontium ranelate: a novel mode of action of optimizing Combretastatin A4 bone formation and resorption. Osteoporos Int 16(Suppl 1):S7–S10PubMedCrossRef 35. Baron R, Tsouderos Y (2002) In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 450:11–17PubMedCrossRef
36. Chattopadhyay N, Quinn SJ, Kifor O (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 74:438–447PubMedCrossRef 37. Brown EM, Pollak M, Hebert SC (1998) The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 49:15–29PubMedCrossRef 38. Boivin G, Farlay D, Simi C, Meunier PJ (2006) Bone strontium distribution and degree www.selleckchem.com/products/JNJ-26481585.html of mineralisation of bone in postmenopausal women treated with strontium ranelate for 2 or 3 years. Osteoporos Int 17:S86 39. Boivin G, Meunier PJ (2006) Bone strontium content reaches a plateau after 3 years of treatment with strontium ranelate 2 g per day. Arthritis Rheum 9(Suppl):S59040 40. Bruyere O, Roux C, Detilleux J et al (2007) Relationship between bone mineral density changes ans fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92(8):3076–3081PubMedCrossRef 41. Bruyere O, Roux C, Badurski J et al (2007) Relationship between change
in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranealte. Cur Med Res Op 23(12):3041–45CrossRef 42. Marquis P, Roux C, de la Loge C et al (2007) Strontium ranelate prevents quality of life impairment in post-menopausal Alanine-glyoxylate transaminase women with established vertebral osteoporosis. Osteoporos Int 19:503–510PubMedCrossRef 43. Dursun N, Dursun E, Yalcin S (2001) Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 55:505–509PubMed 44. Silverman SL, Minshall ME, Shen W et al (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619PubMedCrossRef 45. Nevitt MC, Chen P, Dore RK et al (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis.